VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline CandidatesZacks Investment Research • 04/01/25
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great RecessionThe Motley Fool • 03/28/25
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 03/27/25
Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Market Pullback After a Historic Rally: What Investors Should Do NowZacks Investment Research • 03/21/25
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy PointInvestors Business Daily • 03/21/25
Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 03/19/25
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does NextThe Motley Fool • 03/19/25
Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)Seeking Alpha • 03/10/25
Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic FibrosisBusiness Wire • 03/07/25
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy RatingSeeking Alpha • 03/06/25